【摘 要】
：
背景：內視鏡清洗刷洗作業流程很重要，須高層次消毒劑浸泡時間至少12 分鐘，才可將微生物及細菌孢子全部清除，使用上須謹慎避免發生副作用.目的：運用TRM 手法及創意巧思融入照護流程與作業，提昇OPA 泡消完整率.方法：運用查檢表與問卷測驗進行現況數據搜集如下：1.對OPA 泡消認知不足：醫師30 ％、護理同仁60.5 ％.2.泡消作業，作法不一，自評泡消完整率僅68.2 ％.
【机 构】
：
佛教慈濟醫療財團法人台中慈濟醫院護理部
论文部分内容阅读
背景：內視鏡清洗刷洗作業流程很重要，須高層次消毒劑浸泡時間至少12 分鐘，才可將微生物及細菌孢子全部清除，使用上須謹慎避免發生副作用.目的：運用TRM 手法及創意巧思融入照護流程與作業，提昇OPA 泡消完整率.方法：運用查檢表與問卷測驗進行現況數據搜集如下：1.對OPA 泡消認知不足：醫師30 ％、護理同仁60.5 ％.2.泡消作業，作法不一，自評泡消完整率僅68.2 ％.
其他文献
Background Behcets disease (BD) is a disease of unknown cause which is clinically characterized by recurrent oral and genital ulcers,uveitis,polyarthritis,gastrointestinal involvement,and vasculitis.T
Aim We report a single-center experience in treating 12 patients with severe aplastic anemia (SAA) who received immunosuppressive treatment combined with unrelated cord blood infusion.Methods The medi
Chronic myeloid leukemia (CML) is a clonal disease from hematopoietic stem cells.Surviving leukemia stem cells (LSCs) and progenitor cells are a potential source for CML relapse and progression.Recent
Blast crisis (BC)is highly refractory to therapy and has a poor prognosis.To determine the efficacy of TKIs-Ⅱ com bined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in CML BC,we
Imatinib Mesylate is widely used for the treatment of chronic myelogenous leukaemia (CML),and its effects on CML cells are influenced by several signalling proteins.The research is aimed at determinin
Objective To investigate the peptide extracts from scorpion venom (PESVs) producing an effect on BCR/ABL fusion gene and P210,ras,bcl-xl,JAK1,p53,Bax expression in CML-NOD/SCID mice,to research the me
Objective To determine the relationship of Imatinib (IM) concentration in bone marrow and its therapeutic response in patients with chronic myelogenous leukemia inChina.To explore the underlying mecha
Extensive bone marrow necrosis (BMN) has been described as a rare complication of chronic myeloid leukemia (CML).The prognoses of the patients with BMN were poor.There is no effective treatment for BM
Purpose The clinical outcome of chronic myeloid leukemia (CML) patients has been changed dramatically due to the development of imatinib (IM).However,the emergence of IM resistance,commonly associated
Concurrent manifestation of two myeloid and lymphoid neoplasms in one patient is rare.Due to its rarety,the origin of both diseases is still a matter of debate,whether the two malignancies arose from